人CD3 + CD20 + T细胞的特征。,The Journal of Immunology

当前位置： X-MOL 学术 › J. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

人CD3 + CD20 + T细胞的特征。
The Journal of Immunology ( IF 3.6 ) Pub Date : 2016-07-15 , DOI: 10.4049/jimmunol.1600089
Elisabeth Schuh ₁ , Kerstin Berer ₂ , Matthias Mulazzani ₃ , Katharina Feil ₄ , Ingrid Meinl ₅ , Harald Lahm ₆ , Markus Krane ₇ , Rüdiger Lange ₇ , Kristina Pfannes ₈ , Marion Subklewe ₈ , Robert Gürkov ₉ , Monika Bradl ₁₀ , Reinhard Hohlfeld ₁₁ , Tania Kümpfel ₅ , Edgar Meinl ₅ , Markus Krumbholz ₅

Affiliation

Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig Maximilian University, 82152 Martinsried, Germany; Department of Neuroimmunology, Center for Brain Research, Medical University, 1090 Vienna, Austria;
Max-Planck Institute of Biochemistry, 82152 Martinsried, Germany;
Department of Neurology, University Hospital, Ludwig Maximilian University, 81377 Munich, Germany; Medical Graduate Center, Technical University, 81675 Munich, Germany;
Department of Neurology, University Hospital, Ludwig Maximilian University, 81377 Munich, Germany;
Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig Maximilian University, 82152 Martinsried, Germany;
German Heart Center, Department of Cardiovascular Surgery and Experimental Surgery Laboratory, 80636 Munich, Germany;
German Heart Center, Department of Cardiovascular Surgery and Experimental Surgery Laboratory, 80636 Munich, Germany; German Center for Cardiovascular Research (partner site Munich Heart Alliance), 80636 Munich, Germany;
Department of Medicine III, University Hospital, Ludwig Maximilian University, 81377 Munich, Germany;
Department of Otolaryngology, University Hospital, Ludwig Maximilian University, 81377 Munich, Germany; and.
Department of Neuroimmunology, Center for Brain Research, Medical University, 1090 Vienna, Austria;
Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig Maximilian University, 82152 Martinsried, Germany; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.

抗CD20单克隆抗体可减少多发性硬化症（MS）的复发次数；通常，这种作用仅归因于B细胞的耗竭。然而，最近，已描述了CD3（+）CD20（+）T细胞的子集，该子集也被抗CD20 mAb利妥昔单抗靶向。因为共表达CD3和CD20的细胞的存在是有争议的，并且对该亚群的特征了解得很少，所以我们详细研究了这个问题。在这项研究中，我们确认35％的循环人类T细胞在其表面显示CD20并转录CD3和CD20。我们报告说，这些CD3（+）CD20（+）T细胞遍布胸腺，骨髓和次级淋巴器官。即使在没有炎症的情况下，它们也会在脑脊液中被发现。在MS患者的脑脊液中，它们的发生频率类似于B细胞。从表型上看，这些T细胞富含CD8（+）和CD45RO（+）记忆细胞以及CCR7（-）细胞。在功能上，与缺乏CD20的T细胞相比，它们显示出产生IL-4，IL-17，IFN-γ和TNF-α的频率更高。表达CD20的T细胞对MS患者的免疫调节治疗有不同的反应：芬戈莫德，阿来珠单抗和富马酸二甲酯会降低它们，而那他珠单抗会在血液中成比例地增加它们。经利妥昔单抗耗竭后，它们显示出比CD20（+）B细胞更早且更高的种群。总之，人类CD3（+）CD20（+）T细胞遍布淋巴器官和脑脊液，具有产生不同细胞因子的强大能力，并对MS疾病改良药物有反应。与缺乏CD20的T细胞相比，它们显示出产生IL-4-，IL-17-，IFN-γ-和TNF-α的频率更高。表达CD20的T细胞对MS患者的免疫调节治疗有不同的反应：芬戈莫德，阿来珠单抗和富马酸二甲酯会降低它们，而那他珠单抗会在血液中成比例地增加它们。经利妥昔单抗耗竭后，它们显示出比CD20（+）B细胞更早且更高的种群。总之，人类CD3（+）CD20（+）T细胞遍布淋巴器官和脑脊液，具有产生不同细胞因子的强大能力，并对MS疾病改良药物有反应。与缺乏CD20的T细胞相比，它们显示出产生IL-4-，IL-17-，IFN-γ-和TNF-α的频率更高。表达CD20的T细胞对MS患者的免疫调节治疗有不同的反应：芬戈莫德，阿来珠单抗和富马酸二甲酯会降低它们，而那他珠单抗会在血液中成比例地增加它们。经利妥昔单抗耗竭后，它们显示出比CD20（+）B细胞更早且更高的种群。总之，人类CD3（+）CD20（+）T细胞遍布淋巴器官和脑脊液，具有产生不同细胞因子的强大能力，并对MS疾病改良药物有反应。阿来珠单抗和富马酸二甲酯，而那他珠单抗不成比例地增加血液中的它们。经利妥昔单抗耗竭后，它们显示出比CD20（+）B细胞更早且更高的种群。总之，人类CD3（+）CD20（+）T细胞遍布淋巴器官和脑脊液，具有产生不同细胞因子的强大能力，并对MS疾病改良药物有反应。阿来珠单抗和富马酸二甲酯，而那他珠单抗不成比例地增加血液中的它们。经利妥昔单抗耗竭后，它们显示出比CD20（+）B细胞更早且更高的种群。总之，人类CD3（+）CD20（+）T细胞遍布淋巴器官和脑脊液，具有产生不同细胞因子的强烈能力，并对MS疾病改良药物有反应。

"点击查看英文标题和摘要"

Features of Human CD3+CD20+ T Cells.

Monoclonal Abs against CD20 reduce the number of relapses in multiple sclerosis (MS); commonly this effect is solely attributed to depletion of B cells. Recently, however, a subset of CD3(+)CD20(+) T cells has been described that is also targeted by the anti-CD20 mAb rituximab. Because the existence of cells coexpressing CD3 and CD20 is controversial and features of this subpopulation are poorly understood, we studied this issue in detail. In this study, we confirm that 3-5% of circulating human T cells display CD20 on their surface and transcribe both CD3 and CD20. We report that these CD3(+)CD20(+) T cells pervade thymus, bone marrow, and secondary lymphatic organs. They are found in the cerebrospinal fluid even in the absence of inflammation; in the cerebrospinal fluid of MS patients they occur at a frequency similar to B cells. Phenotypically, these T cells are enriched in CD8(+) and CD45RO(+) memory cells and in CCR7(-) cells. Functionally, they show a higher frequency of IL-4-, IL-17-, IFN-γ-, and TNF-α-producing cells compared with T cells lacking CD20. CD20-expressing T cells respond variably to immunomodulatory treatments given to MS patients: they are reduced by fingolimod, alemtuzumab, and dimethyl fumarate, whereas natalizumab disproportionally increases them in the blood. After depletion by rituximab, they show earlier and higher repopulation than CD20(+) B cells. Taken together, human CD3(+)CD20(+) T cells pervade lymphatic organs and the cerebrospinal fluid, have a strong ability to produce different cytokines, and respond to MS disease modifying drugs.

更新日期：2019-11-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文